Half Sinemet Cr (Carbidopa, Levodopa)

Half Sinemet Cr is indicated for the symptomatic treatment of Parkinson’s disease and related parkinsonian disorders.

• Management of motor fluctuations in Parkinson’s disease.
• Adjunct therapy to improve daily “on” time.
• Treatment of early‑stage Parkinsonian syndrome.
• Support for patients experiencing bradykinesia and rigidity.
• Option for patients who have responded to levodopa therapy but need reduced peripheral side effects.
• Use in combination with other antiparkinson agents as prescribed.

The safety profile of Half Sinemet Cr reflects the combined actions of levodopa and carbidopa, with side effects ranging from mild and frequent to rare but serious.

Common

• Nausea or vomiting.
• Headache.
• Dizziness or light‑headedness, especially when standing.
• Orthostatic hypotension.
• Insomnia or vivid dreams.
• Dry mouth.

Serious

• Dyskinesia (involuntary movements).
• Hallucinations or psychotic symptoms.
• Severe hypotension or syncope.
• Neuroleptic malignant‑like syndrome (rare).

When prescribing Half Sinemet Cr, clinicians consider several precautionary factors to ensure safe and effective use.

• Assess cardiovascular status before initiation, especially for patients with a history of hypertension or arrhythmia.
• Monitor for emerging psychiatric symptoms such as hallucinations or confusion.
• Evaluate renal and hepatic function periodically, adjusting therapy as needed.
• Adjust dose in patients with known sensitivity to levodopa or carbidopa.
• Use caution in individuals with a personal or family history of melanoma.
• Avoid abrupt discontinuation to reduce the risk of withdrawal or worsening motor symptoms.

Half Sinemet Cr can interact with other medicines, affecting its efficacy or safety.

Avoid

• Non‑selective MAO inhibitors (e.g., phenelzine, tranylcypromine).
• Antipsychotics that block dopamine receptors (e.g., haloperidol, chlorpromazine).
• Sympathomimetic agents that may increase blood pressure (e.g., ephedrine, pseudoephedrine).

Use with caution

• Selective MAO‑B inhibitors (e.g., selegiline, rasagiline).
• Antihypertensive drugs, including beta‑blockers and calcium‑channel blockers.
• Iron supplements, antacids, or high‑protein meals that can reduce levodopa absorption.